Key facts
- Notable investors include Investissement Quebec, adMare Bioinnovations.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Ocythera
- ·The full record, as it builds
Funding rounds
No funding rounds for Ocythera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ocythera
Developer of selective and non-retinoid small molecule inhibitors designed to modulate local retinoic acid signaling for the treatment of rare bone diseases. The company offers therapies that target specific enzymes in the retinoic acid metabolism pathway, enabling clients to access safer and effective treatments that avoid the systemic toxicity of conventional retinoids for patients with rare bone disorders like Hereditary Multiple Osteochondromas and Fibrodysplasia Ossificans Progressiva.
- Sector
- Healthcare
- HQ
- Montreal, Canada
- Founded
- 2024
- Employees
- 3
- Website
- ocythera.com/
- Ownership
- Privately Held (backing)
Ocythera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ocythera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ocythera in its N-PORT filings yet. We sweep new filings monthly.